
Idexx Laboratories (IDXX) is highlighted by Zacks as a top momentum stock, despite its #3 (Hold) rank, driven by an 'A' Momentum Style Score and 'B' VGM Score. The company's shares have risen 19.1% over the past four weeks, supported by recent upward revisions to fiscal 2025 earnings estimates, now at $12.39 per share, and a historical average earnings surprise of 6.1%. This combination of strong technical performance and positive earnings outlook positions IDXX for consideration by investors focused on momentum strategies.
Idexx Laboratories (IDXX) is presenting a compelling case for momentum-focused investors, underpinned by both strong technical performance and positive fundamental revisions. The company's stock has surged 19.1% over the past four weeks, a move validated by its 'A' Momentum Style Score from Zacks. This price action is not speculative; it is supported by an improving earnings outlook. Specifically, four analysts have revised their fiscal 2025 earnings estimates upward within the last 60 days, lifting the Zacks Consensus Estimate by $0.23 to $12.39 per share. This trend is consistent with the company's history of outperformance, as evidenced by an average earnings surprise of +6.1%. While the stock holds a neutral Zacks Rank of #3 (Hold), its strong complementary scores, including a 'B' for the composite VGM, suggest that the positive momentum and earnings trends are significant enough to warrant investor attention.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment